Proteasome Inhibitors Global Market Report 2024

The proteasome inhibitors market size has grown strongly in recent years. It will grow from $1.86 billion in 2023 to $2.03 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The expansion observed in the historical period can be attributed to scientific breakthroughs, advancements in clinical research and trials, FDA approvals, an increase in cancer cases, and innovations in drug delivery methods.

The proteasome inhibitors market size is expected to see strong growth in the next few years. It will grow to $2.89 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The anticipated growth in the forecast period can be attributed to precision medicine approaches, the development of next-generation inhibitors, growth in healthcare infrastructure, combinations of targeted therapies, and increased adoption in emerging markets. Key trends expected in the forecast period include combinations of immunotherapy, selective proteasome inhibition, inhibitors with longer half-lives, oral formulations, and treatments for resistant cancer variants.

The proteasome inhibitors market is poised for growth, driven by the increasing prevalence of pancreatic cancer. Pancreatic cancer, developing in the pancreas cells, is a target for proteasome inhibitors due to the critical role of proteasomes in promoting cancer cell survival and growth. Proteasome inhibitors disrupt cancer cell survival, inhibit tumor growth, and prevent metastasis. According to the American Society of Clinical Oncology (ASCO) reports in March 2023, an estimated 64,050 adults were diagnosed with pancreatic cancer in the US, leading to 50,550 deaths. Globally, 495,773 people were diagnosed, and 466,003 died of pancreatic cancer in 2020. This prevalence underscores the driving force behind the growth of the proteasome inhibitors market.

The growth of the proteasome inhibitors market is further propelled by increasing government funding for research and development. Government funding plays a crucial role in advancing proteasome inhibitor research by financially supporting scientific investigations, clinical trials, and drug development. For example, the National Cancer Institute in the US received a budget of $7.3 billion in fiscal year 2023, a $408 million increase over 2022. This substantial funding boost contributes to driving the growth of the proteasome inhibitors market.

Investments are emerging as a key trend in the proteasome inhibitors market, with major companies investing in the development and commercialization of these inhibitors. In September 2022, QLi5 Therapeutics GmbH, a Germany-based developer of novel proteasome inhibitors, secured a significant investment of $10.96 million from venture capital firms such as SV Investment, KHAN Technology Transfer Fund I, Atinum Investment Co., Ltd., and Daol Investment & Securities Co., Ltd. This funding supports QLi5's efforts to advance its pipeline of distinct proteasome inhibitors for cancer, inflammatory, and autoimmune disorders, contributing to the market's growth.

Major companies in the proteasome inhibitors market are strategically focusing on developing novel generic medications, including single-dose vials. For instance, Dr. Reddy's Laboratories, an India-based pharmaceutical company, launched Bortezomib for Injection, 3.5 mg, a generic equivalent of Velcade (bortezomib) injection. This single-dose vial presentation for subcutaneous or intravenous use enhances treatment options for adult patients with multiple myeloma.

In October 2022, Karyopharm Therapeutics Inc., a US-based pharmaceutical company, collaborated with Bristol-Myers Squibb to assess mezigdomide in patients who have received previous treatments. This collaboration with Bristol-Myers Squibb, a provider of innovative medicines, demonstrates a strategic approach to advancing research and development in the proteasome inhibitors market.

Major companies operating in the proteasome inhibitors market report are Pfizer Inc., Johnson And Johnson, AbbVie, Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Sigma-Aldrich, Zydus Pharmaceuticals, Onyx Pharmaceuticals Inc., Tocris Bioscience, Accuitis Inc., TG Therapeuticsn Inc., QLi5 Therapeutics GmbH, Progenra Inc., Nurix Inc., Cephalon Inc., Cleave Therapeutics, Lifesensors Inc., MimiVax LLC, Apotex Inc.

North America was the largest region in the proteasome inhibitors market in 2023. The regions covered in the proteasome inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the proteasome inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of products in proteasome inhibitors include Velcade, Kyprolis, Ninlaro, and others. Velcade, for instance, is the brand name for the prescription drug bortezomib. Bortezomib, as a proteasome inhibitor, is utilized in the treatment of multiple myeloma cancer. Various drugs fall under this category, such as bortezomib, carfilzomib, and ixazomib. Proteasome inhibitors are employed to treat diverse indications, including lymphoma, mantle cell lymphoma, and multiple myeloma. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, with end-users primarily consisting of hospitals, specialty clinics, and others.

The proteasome inhibitors market research report is one of a series of new reports that provides proteasome inhibitors market statistics, including proteasome inhibitors industry global market size, regional shares, competitors with a proteasome inhibitors market share, detailed proteasome inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the proteasome inhibitors industry. This proteasome inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proteasome inhibitor market consists of sales of marizomib, oprozomib, and delanzomib, epoxyketone proteasome inhibitors, non-peptidic proteasome inhibitors, panobinostat and olaparib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.